检索结果-南通市图书馆

长期定位耕作模式对小麦^(13)C同化物分配和籽粒产量形成的影响

在线全文

学校读者我要写书评

暂无评论

应用生态学报 2024年第4期35卷 926-932页

作者：王庆源陈甜于振文张振张永丽石玉山东农业大学农学院/小麦育种全国重点实验室/农业部作物生理生态与耕作重点实验室山东泰安271018

明确长期定位耕作模式对小麦籽粒产量的影响及其生理原因,可为小麦的高产高效生产提供理论依据与技术支撑。以济麦22为试验材料,研究了连续14年旋耕(R)、少免耕(S)和隔两年深松+少免耕(SS)3种耕作模式对小麦植株冠层光截获、同化物转运... 详细信息

明确长期定位耕作模式对小麦籽粒产量的影响及其生理原因,可为小麦的高产高效生产提供理论依据与技术支撑。以济麦22为试验材料,研究了连续14年旋耕(R)、少免耕(S)和隔两年深松+少免耕(SS)3种耕作模式对小麦植株冠层光截获、同化物转运分配和籽粒产量形成的影响。结果表明:小麦叶面积指数在开花后14~28 d表现为SS处理显著高于其他处理;开花后21 d, SS处理小麦冠层的上层和中层光合有效辐射截获率和截获量均显著高于R和S处理;开花后同化物对籽粒的贡献率和^(13)C同化物在籽粒中的分配比例表现为SS处理均显著高于其他处理,且最大灌浆速率和平均灌浆速率均显著高于其他处理;SS处理的千粒重较R和S处理分别提高了8.7%和9.6%,籽粒产量较R和S处理分别提高了14.2%和19.4%。SS处理显著改善了小麦冠层的光能利用,促进了干物质的积累和转运,提高了籽粒灌浆速率,增加了粒重,获得了最高的籽粒产量,是本试验条件下的最优耕作模式。

关键词：耕作模式光截获 ^(13)C同化物籽粒灌浆籽粒产量

Exploratory clinical study of chidamide,an oral subtype-selective histone deacetylase inhibitor,in combination with exemestane in hormone receptor-positive advanced breast cancer

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2018年第6期30卷 605-612页

作者： qingyuan zhang Tao Wang Cuizhi Geng Yue zhang Jinwen zhang Zhiqiang Ning Zefei Jiang Department of Medical Oncology Harbin Medical University Cancer HospitalHarbin 150081China Department of Breast Cancer the 307th hospital of Chinese People's Liberation ArmyBeijing 100071China The Fourth Hospital of Hebei Medical University Shijiazhuang 050011China Shenzhen Chipscreen Biosciences Shenzhen 518057China

Objective: The recurrence or progression under endocrine therapy in hormone receptor-positive(HR+)advanced breast cancer(ABC) remained a critical clinical challenge.Chidamide is an oral subtype-selective histone deacetylase(HDAC) inhibitor with multiple functions in tumor growth inhibition and microenvironment modulation via epigenetic reprogramming.The purpose of this study was to evaluate the safety,pharmacokinetics(PK),and preliminary efficacy of chidamide in combination with exemestane in HR+ ABC patients.Methods: Eligible patients were postmenopausal women with HR+ ABC recurrent or progressed to at least one endocrine therapy.Blood samples were obtained in the run-in period and the first day of combination treatment for PK analysis.In combination treatment,patients were given exemestane 25mg daily and chidamide 30mg twice a week(BIW) until progression of disease or intolerable toxicities.A treatment cycle was defined as 4 weeks.Safety,PK parameters,and preliminary efficacy were evaluated.Results: A total of 20 patients were enrolled between July and December,2015.The median number of treatments cycle was 5.2(20.8 weeks) with 2 patients still on treatment at the data cut-off date of October,2017.The treatment-related adverse events(AE) ≥ grade 3 in more than 2 patients were neutropenia(35%),thrombocytopenia(30%),and leucopenia(20%).The plasma exposure of exemestane was consistent in the presence or absence of chidamide.A slight increase in chidamide exposure was noted in the presence of exemestane,probably due to the inter-and intra-patient variations.The best response in 16 evaluable patients was assessed by Response Evaluation Criteria in Solid Tumors(RECIST),including 4 patients with partial response,10 patients with stable disease.The median progression-free survival(PFS) was 7.6 months.Conclusions: The combination of chidamide with exemestane was generally well tolerated with promising preliminary efficacy in HR+ ABC patients.The overall results from this study encourage further pivotal trial in this pat

关键词： Advanced breast cancer hormone receptor-positive chidamide exemestane

基于场景线性化重塑的用户侧储能容量高效规划方法

在线全文

学校读者我要写书评

暂无评论

电力系统自动化 2024年第5期48卷 30-37页

作者：江昇文书礼朱淼马建军张庆源电力传输与功率变换控制教育部重点实验室(上海交通大学) 上海市200240 上海交通大学国家电投智慧能源创新学院上海市200240 沈阳微控新能源技术有限公司辽宁省沈阳市110000

推进用户侧分布式光储一体化发展是提高新型电力系统新能源消纳能力的重要举措。然而,储能高昂的投资成本阻碍了用户侧光储系统的推广进程,亟需合理的储能容量优化配置方案为用户提供更加理性的决策依据,以提升系统经济性和环境友好性... 详细信息

推进用户侧分布式光储一体化发展是提高新型电力系统新能源消纳能力的重要举措。然而,储能高昂的投资成本阻碍了用户侧光储系统的推广进程,亟需合理的储能容量优化配置方案为用户提供更加理性的决策依据,以提升系统经济性和环境友好性。现有容量规划方法往往基于典型场景进行储能运行模拟,未考虑全年每个典型场景之间的功率波动特征以及某些极端场景对于容量配置结果的影响,难以保证规划结果的准确性。为此,文中提出了一种基于场景线性化重塑的用户侧储能容量高效规划方法。首先,以聚类结果中的典型场景为基,通过最小二乘法近似地线性表示全年中的极端场景;其次,将场景线性化结果嵌入储能全年运行约束中,并通过重新构造决策变量来减小优化问题的规模;最后,通过实际算例分析了用户侧配置储能的经济效益,并将所提出的规划方法与已有方法进行仿真结果对比。结果表明,所提出的规划方法能够减小精确模型运行所需的决策变量规模,在提升计算效率的同时取得比已有近似方法更准确的规划结果。

关键词：新型电力系统用户侧储能容量规划典型场景场景线性化重塑聚类算法

银行竞争与行业资源配置——来自中国规模以上工业企业的证据

在线全文

学校读者我要写书评

暂无评论

经济学动态 2024年第2期 52-71页

作者：章尹赛楠李青原武汉大学经济与管理学院 430064

资源配置效率的提高是实现经济高质量发展的基础,银行作为中国金融体系的核心,在信贷资源配置和企业融资方面发挥着关键作用。本文以1998—2013年中国工业企业数据为样本,借助中国商业银行分支机构信息构建银行竞争水平指标,检验了银行... 详细信息

资源配置效率的提高是实现经济高质量发展的基础,银行作为中国金融体系的核心,在信贷资源配置和企业融资方面发挥着关键作用。本文以1998—2013年中国工业企业数据为样本,借助中国商业银行分支机构信息构建银行竞争水平指标,检验了银行竞争对中国行业资源配置效率的影响。研究发现,银行竞争能够通过缓解企业融资约束促进具有更高生产效率的非国有企业固定资产投资和研发支出的增加,提高这类企业的经营绩效,从而改善城市-行业的资源错配。当行业面临的融资约束更高、融资依赖更强、会计信息质量更好及地区市场化程度更高时,银行竞争对资源配置的促进作用更为显著。以上结论丰富了金融部门竞争对资源配置影响的研究,也为中国金融市场化改革和普惠金融政策的实施提供了理论和实证支撑。

关键词：银行分支机构银行竞争资源配置全要素生产率

Erratum to:Bioinformatic analysis for potential biological processes and key targets of heart failure-related stroke

在线全文

学校读者我要写书评

暂无评论

Journal of Zhejiang University-Science B(Biomedicine & Biotechnology) 2024年第4期25卷 359-359页

作者： Chiyu LIU Sixu CHEN Haifeng zhang Yangxin CHEN qingyuan GAO Zhiteng CHEN Zhaoyu LIU Jingfeng WANG Department of Cardiology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhou 510120China Laboratory of Cardiac Electrophysiology and Arrhythmia in Guangdong Province Guangzhou 510120China Guangdong Provincial Key Laboratoryof Malignant Tumor Epigenetics and Gene Regulation Sun Yat-Sen Memorial HospitalSun Yat-Sen UniversityGuangzhou 510120China

Erratum to:J Zhejiang Univ-Sci B(Biomed&Biotechnol)202122(9):718-732 https:/***/10.1631/jzus.B2000544.The original version of this article(Liu et al.,2021)unfortunately contained a mistake:statement of equal contribution is missing.This correction article shows that Chiyu LIU and Sixu CHEN contributed equally to this work.The original article has been corrected.

关键词： statement correction potential

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

单相脉冲整流器故障在线智能诊断实验设计

实验室研究与探索 2024年第5期43卷 36-41页

作者：王青元张坤苟斌西南交通大学电气工程学院成都611756

针对高速列车电力牵引系统中单相脉冲整流器的功率器件开路故障和传感器故障,设计了基于数据驱动的故障在线智能诊断实验。首先,对单相脉冲整流器系统进行数学建模,分析功率器件开路故障的故障拓扑和传感器故障的故障机理;然后,基于极... 详细信息

针对高速列车电力牵引系统中单相脉冲整流器的功率器件开路故障和传感器故障,设计了基于数据驱动的故障在线智能诊断实验。首先,对单相脉冲整流器系统进行数学建模,分析功率器件开路故障的故障拓扑和传感器故障的故障机理;然后,基于极限学习机算法和非线性自回归结构设计智能诊断模型,并将故障在线智能诊断实验分为离线训练和在线验证2个阶段;最后,基于RT Box半实物仿真器搭建快速原型控制实验平台,对故障模型和诊断模型进行实验验证。实验结果表明,构建的单相脉冲整流器故障在线智能诊断模型可以在1/4个基波周期内检测到故障的发生,并在3/4个基波周期内识别出具体故障类型。

关键词：单相脉冲整流器故障诊断功率器件开路故障传感器故障半实物仿真器

CEA、CA724、CA19-9、CA125联合检测在胃癌患者中的运用价值

在线全文

学校读者我要写书评

暂无评论

中国医药指南 2024年第14期22卷 39-42页

作者：张清渊厦门大学附属中山医院厦禾分部检验科厦门361000

目的观察血清癌胚抗原(CEA)、糖类抗原724(CA724)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)联合检测对胃癌患者的临床价值。方法选取我院2020年5月至2023年5月收治的176例胃癌患者作为恶性组,按照2∶1配对原则选取同期、同年段88名... 详细信息

目的观察血清癌胚抗原(CEA)、糖类抗原724(CA724)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)联合检测对胃癌患者的临床价值。方法选取我院2020年5月至2023年5月收治的176例胃癌患者作为恶性组,按照2∶1配对原则选取同期、同年段88名健康对照作为对照组。比较两组血清CEA、CA724、CA19-9、CA125水平,分析胃癌患者血清各指标与临床病理特征的关系,ROC曲线评估血清各指标联合对胃癌的诊断价值。结果恶性组血清CEA、CA724、CA19-9、CA125水平高于对照组(P<0.05);胃癌患者分化程度、TNM分期、淋巴结转移、远处转移血清CEA、CA724、CA19-9、CA125水平比较,差异有统计学意义(P<0.05);血清CEA、CA724、CA19-9、CA125与分化程度、TNM分期、淋巴结转移、远处转移呈正相关(P<0.05);血清CEA、CA724、CA19-9、CA125联合诊断胃癌的AUC大于各指标单独诊断(P<0.05)。结论胃癌患者血清CEA、CA724、CA19-9、CA125表达较高,与患者分化程度、TNM分期、淋巴结转移、远处转移有关,且联合检测胃癌具有较高参考价值。

关键词：胃癌癌胚抗原糖类抗原724 糖类抗原19-9 糖类抗原125

The prognostic value of programmed cell death ligand 1expression in non-Hodgkin lymphoma:a meta-analysis

在线全文

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2018年第3期15卷 290-298页

作者： Shu Zha Minghui zhang Yu zhang Hongxue Meng Yan Wang Yupeng Liu Jing Jing Lan Huang Mengqi Sun Yue zhang qingyuan zhang Department of Medical Oncology Harbin Medical University Cancer Hospital Department of Radiotherapy Harbin Medical University Cancer Hospital Department of Pathology Harbin Medical University Cancer Hospital Department of Medical Oncology Heilongjiang Provincial Hospital Department of Epidemiology Public Health College of Harbin Medical University

Objective: Although the prognostic value of programmed cell death-ligand 1(PD-L1) expression in non-Hodgkin lymphoma(NHL) has been evaluated in many studies, the results remain controversial. To investigate the prognostic role of PD-L1 expression and the association between PD-L1 expression and clinicopathological features of NHL, we performed a meta-analysis.Methods: The Pub Med, EMBASE, and Cochrane Library databases were searched up to November 30, 2017. The hazard ratio(HR), 95% confidence interval(CI), and odds ratios(OR) with 95% CIs were combined to evaluate the association of PD-L1 expression with overall survival(OS) and clinicopathological features. Review manager 5.3 and STATA 12.0 were used in this meta-analysis.Results: A total of 2,005 patients across nine studies were enrolled in our meta-analysis, and the pooled results showed that high PD-L1 expression was associated with a poor prognosis(HR=2.04, 95% CI: 1.18–3.54, P=0.01). In the subgroup analysis according to histology types, pooled results demonstrated that an increased PD-L1 expression was an unfavorable prognostic factor for diffuse large B-cell lymphoma(HR=1.92, 95% CI: 1.06–3.48, P=0.03) but not for natural killer/T-cell lymphoma(HR=2.41, 95%CI: 0.47–12.22, P=0.29). Pooled ORs indicated that PD-L1 expression was higher in NHL with international prognostic indices of≥3. However, PD-L1 expression had no correlation with gender, age, disease stage, lactate dehydrogenase level, B symptoms, and germinal center B-cell-like lymphoma.Conclusions: High PD-L1 expression was a poor prognostic biomarker in patients with NHL. Because of our limited sample size,high-quality studies with larger sample sizes are needed to validate our results.

关键词：房间规划价值死亡淋巴瘤表达式 Med 数据库

A multi-center,open-label,randomized,parallel-controlled phase II study comparing pharmacokinetic,pharmacodynamics and safety of ripertamab(SCT400)to rituximab(Mab Thera?)in patients with CD20-positive B-cell non-Hodgkin lymphoma

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2022年第6期34卷 601-611页

作者： Xiaohong Han Mingzhi zhang Huaqing Wang qingyuan zhang Wei Li Miaowang Hao Yuhuan Gao Jie Jin Hanyun Ren Yun Tang Xiaonan Hong Xiaoyan Ke Hang Su Lin Gui Jianmin Luo Liangzhi Xie Wenlin Gai Yuankai Shi Clinical Pharmacology Research Center Peking Union Medical College HospitalState Key Laboratory of Complex Severe and Rare DiseasesNMPA Key Laboratory for Clinical Research and Evaluation of DrugBeijing Key Laboratory of Clinical PK&PD Investigation for Innovative DrugsChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100730China Department of Oncology the First Affliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Medical Oncology Tianjin People's HospitalTianjin 300121China Department of Medical Oncology Harbin Medical University Cancer HospitalHarbin 150081China Oncology Department of Cancer Center the First Hospital of jilin UniversityChangchun 130021China Department of Hematology Tangdu HospitalAir Force Medical UniversityXi'an 710038China Department of Hematology the Fourth Hospital of Hebei Medical UniversityShijiazhuang 050011China Department of Hematology the First Affliated Hospital of Zhejiang UniversityHangzhou 310003China Department of Hematology Peking University First HospitalBeijing 100034China Department of Hematology West China HospitalSichuan UniversityChengdu 610041China Department of Medical Oncology Fudan University Shanghai Cancer CenterShanghai 2032China Department of Hematology Peking University Third HospitalBeijing 100191China Department of Lymphoma the Fifth Medical Center of PLA General HospitalBeijing 100071China Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021China Department of Hematology the Second Hospital of Hebei Medical UniversityShijazhuang 050000China Beijing Engineering Research Center of Protein and Antibody Sinocelltech Ltd.Beijing 100176China

Objective:This multi-center,open-label,randomized,parallel-controlled phaseⅡstudy aimed to compare the pharmacokinetics(PK),pharmacodynamics(PD)and safety profile of ripertamab(SCT400),a recombinant antiCD20 monoclonal antibody,to rituximab(MabThera^(■))in patients with CD20-positive B-cell non-Hodgkin lymphoma(NHL).Methods:Patients with CD20-positive B-cell NHL who achieved complete remission or unconfirmed complete remission after standard treatment were randomly assigned at a 1:1 ratio to receive a single dose of ripertamab(375mg/m^(2))or rituximab(MabThera^(■),375 mg/m^(2)).PK was evaluated using area under the concentration-time curve(AUC)from time 0 to d 85(AUC_(0-85d)),AUC from time 0 to week 1(AUC0-1 w),AUC from time 0 to week 2(AUC_(0-2 w)),AUC from time 0 to week 3(AUC_(0-3 w)),AUC from time 0 to week 8(AUC_(0-8 w)),maximum serum concentration(C_(max)),terminal half-life(T_(1/2)),time to maximum serum concentration(T_(max))and clearance(CL).Bioequivalence was confirmed if the 90%confidence interval(90%CI)of the geometric mean ratio of ripertamab/rituximab was within the pre-defined bioequivalence range of 80.0%-125.0%.PD,immunogenicity,and safety were also evaluated.Results:From December 30,2014 to November 24,2015,a total of 84 patients were randomized(ripertamab,n=42;rituximab,n=42)and the PK analysis was performed on 76 patients(ripertamab,n=38;rituximab,n=38).The geometric mean ratios of ripertamab/rituximab for AUC_(0-85d),ATC_(0-inf),and Cmaxwere 96.1%(90%CI:87.6%-105.5%),95.9%(90%CI:86.5%-106.4%)and 97.4%(90%CI:91.6%-103.6%),respectively.All PK parameters met the pre-defined bioequivalence range of 80.0%-125.0%.For PD and safety evaluation,there was no statistical difference in peripheral CD 19-positive B-cell counts and CD20-positive B-cell counts at each visit,and no difference in the incidence of anti-drug antibodies was observed between the two groups.The incidences of treatment-emergent adverse events and treatment-related adverse events were also comparable between the two groups.Conclusion

关键词： Anti-CD20 monoclonal antibody non-Hodgkin lymphoma pharmacokinetics ripertamab rituximab safety